Ticker
ADPT

Price
11.20
Stock movement up
+0.02 (0.18%)
Company name
Adaptive Biotechnologies Corp
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
1.59B
Ent value
1.78B
Price/Sales
10.31
Price/Book
2.88
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-67.39%
3 year return
-36.72%
5 year return
-
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ADPT does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales10.31
Price to Book2.88
EV to Sales11.54

FINANCIALS

Per share

Loading...
Per share data
Current share count142.23M
EPS (TTM)-1.62
FCF per share (TTM)-1.76

Income statement

Loading...
Income statement data
Revenue (TTM)154.52M
Gross profit (TTM)102.02M
Operating income (TTM)-230.75M
Net income (TTM)-229.37M
EPS (TTM)-1.62
EPS (1y forward)-1.61

Margins

Loading...
Margins data
Gross margin (TTM)66.02%
Operating margin (TTM)-149.33%
Profit margin (TTM)-148.44%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash114.81M
Net receivables22.52M
Total current assets419.12M
Goodwill118.97M
Intangible assets8.11M
Property, plant and equipment0.00
Total assets858.19M
Accounts payable5.96M
Short/Current long term debt113.52M
Total current liabilities115.07M
Total liabilities304.94M
Shareholder's equity553.25M
Net tangible assets426.13M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-198.94M
Capital expenditures (TTM)48.98M
Free cash flow (TTM)-247.92M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-41.46%
Return on Assets-26.73%
Return on Invested Capital-40.83%
Cash Return on Invested Capital-44.13%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open11.05
Daily high11.24
Daily low10.93
Daily Volume823K
All-time high67.74
1y analyst estimate15.30
Beta0.91
EPS (TTM)-1.62
Dividend per share-
Ex-div date-
Next earnings date1 Nov 2022

Downside potential

Loading...
Downside potential data
ADPTS&P500
Current price drop from All-time high-83.47%-12.18%
Highest price drop-90.55%-56.47%
Date of highest drop13 Jun 20229 Mar 2009
Avg drop from high-43.60%-11.38%
Avg time to new high50 days12 days
Max time to new high402 days1805 days
COMPANY DETAILS
ADPT (Adaptive Biotechnologies Corp) company logo
Marketcap
1.59B
Marketcap category
Small-cap
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Employees
858
Investor relations
-
SEC filings
CEO
Chad Robins
Country
USA
City
Seattle
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Every investor in Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) should be aware of the most powerful shareholder...
September 15, 2022
The Seattle-based biotech can tap three tranches of funding under an agreement with health care investment firm OrbiMed.
September 14, 2022
SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system int...
September 12, 2022
SEATTLE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the geneti...
September 2, 2022
Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.
August 14, 2022
Joining the call today are Chad Robins, our CEO and co-founder; and Tycho Peterson, our chief financial officer. In addition, Harlan Robins, Adaptive's chief scientific officer and co-founder; Nitin ...
August 4, 2022
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 7.50% and 0.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
August 3, 2022
SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...
August 3, 2022
Adaptive Biotechnologies (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
August 2, 2022
NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
July 28, 2022
Next page